GOVX GeoVax Labs, Inc.
-
GeoVax Labs Beat Consensus Estimates
Monday, July 27, 2026 · 12:00 AM ET
GeoVax Labs (GOVX) reported a loss of $0.97 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $2.16 per share. The company beat consensus estimates by 55.09% while revenue fell 100.00% compared to the same quarter a year ago.
GeoVax Labs, Inc., is a development stage biotechnology company. It is engaged in developing human vaccines for diseases caused by Human Immunodeficiency Virus (HIV).
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.97)
Earnings Whisper®
—
Consensus Estimate
($2.16)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth